Patients who have had systemic (chemotherapy, biologic therapy or radiotherapy) within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study Patients who have had chemotherapy, immunotherapy, or investigational therapy, within weeks ( weeks for nitrosoureas or mitomycin C), or palliative radiotherapy within weeks prior to the first dose of the study drug Patients must not have received nitrosoureas or mitomycin-C within days prior to sub-study registration Prior chemotherapy is allowed, including platinum therapy; patients must not have received chemotherapy for weeks prior to the initiation of study treatment and must have recovery =< grade from any adverse events from any prior chemotherapy (other than alopecia); patients must not have had nitrosoureas or mitomycin C for weeks prior to the initiation of study treatment Receipt of cytotoxic chemotherapy within weeks ( weeks for nitrosoureas and mitomycin C) of scheduled CD dosing. Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within one month prior to study entry ( weeks for nitrosoureas or Mitomycin C). Patients who have had chemotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study Systemic anticancer therapy within three weeks of study entry, except for nitrosoureas or mitomycin C within six weeks. Mitomycin C/nitrosoureas less than or equal to weeks prior to registration Treatment with surgery or chemotherapy within days prior to study entry ( days for nitrosoureas or mitomycin C) Participants who have had chemotherapy, biologic therapy, investigational agents, radiotherapy, or major surgery within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Participants who have had chemotherapy, radiotherapy, or major surgery within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study Participants who have had chemotherapy, radiotherapy, biologic therapy, major surgery, or another investigational agent within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study; patients who have received prior PARP inhibitor will not be excluded; patients who have received prior CHK inhibitor will be excluded Patients who have had radiotherapy (except for palliative reasons), immunotherapy or chemotherapy during the previous weeks ( weeks for nitrosoureas or mitomycin) before treatment, or those who have ongoing toxic manifestations of previous treatments, with the exception of alopecia, of grade higher than Participants who have had chemotherapy, immune therapy, other investigational therapy, major surgery, or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study The patient has received chemotherapy or radiotherapy within weeks or has received nitrosoureas or mitomycin C within weeks prior to the first dose of study drug. At least three weeks since the last anticancer therapy, including investigational drugs and radiotherapy, and at least six weeks since nitrosoureas and mitomycin C(systemic). Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study treatment with cytotoxic agents, or treatment with biologic agents within weeks prior to treatment with APSF ( weeks for mitomycin C or nitrosoureas). Patients who have had chemotherapy or radiotherapy within weeks or five half-lives whichever is shorter ( weeks for nitrosoureas or mitomycin C) prior to entering the study COHORT : HORMONE RECEPTOR POSITIVE BREAST CANCER: Patients who have received chemotherapy in the previous weeks ( weeks for nitrosoureas or mitomycin); other investigational agents within weeks or a PD/PDL agent within weeks prior to first dose of study treatment COHORT : TRIPLE NEGATIVE BREAST CANCER: Patients who have received chemotherapy in the previous weeks ( weeks for nitrosoureas or mitomycin); other investigational agents within weeks or a PD/PDL agent within weeks prior to study enrollment COHORT : ENDOMETRIAL CANCER: Patients who have received chemotherapy in the previous weeks ( weeks for nitrosoureas or mitomycin); other investigational agents within weeks or a PD/PDL agent within weeks prior to study enrollment Subjects who have had chemotherapy or radiotherapy within weeks ( weeks for immunotherapy; weeks for nitrosoureas or mitomycin C) prior to starting the study agent. Patients who have received chemotherapy in the previous weeks ( weeks for nitrosoureas or mitomycin) Treatment with chemotherapy or other investigational agents within days (or at least x the half-life of the drug) prior to day cycle of Minnelide ( weeks for nitrosoureas or Mitomycin C). Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) or at least half-lives, whichever is longer, prior to entering the study mCRPC EXPANSION COHORT: The patient has received chemotherapy, radiotherapy, biologic agents or enzalutamide within weeks before the first dose of study treatment (nitrosoureas or mitomycin within weeks); however, for patients receiving abiraterone, they must discontinue the medication at least days before the first dose of study treatment Patient who has had systemic therapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to study entry Patients will be excluded if they have received previous chemotherapy, immunotherapy, radiotherapy or any other investigational therapy within weeks ( weeks for nitrosoureas or mitomycin C) or half-lives for targeted therapies prior to this study entry. Patients who have had prior chemotherapy or any other investigational drug within days of registration or prior radiotherapy to the study treatment volume; prior surgery is allowed; there must be at least weeks between mitomycin or nitrosoureas and any new therapy Have received chemotherapy < days prior to CD, or < days for mitomycin or nitrosoureas; PHASE I STUDY ELIGIBILITY CRITERIA:\r\nPatients who have received chemotherapy, radiotherapy, any other investigational agents within weeks ( weeks for nitrosoureas or mitomycin) prior to study enrollment PHASE II STUDY COHORT TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nPatients who have received chemotherapy in the previous weeks ( weeks for nitrosoureas or mitomycin); or who received radiotherapy or any other investigational agents within weeks prior to study enrollment PHASE II COLORECTAL CANCER COHORT (MEDI+C ONLY):\r\nPatients who have received chemotherapy, radiotherapy, any other investigational agents within weeks ( weeks for nitrosoureas or mitomycin) prior to study enrollment Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study; for investigational targeted therapies, patients will need to clear for half-lives (not applicable to standard of care therapies) Patients will be excluded if they have received previous chemotherapy, immunotherapy, radiotherapy or any other investigational therapy within weeks ( weeks for nitrosoureas or mitomycin C) or half-lives for non-cytotoxic agents prior to this study entry. Chemotherapy: Chemotherapy within weeks of PV- administration ( weeks for nitrosoureas or mitomycin C). Subjects with HCC who have been on a stable dose of sorafenib for at least weeks will be candidates for enrollment in Expansion Cohort Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or systemic mitomycin C) before the initiation of study treatment Ongoing or previous anti-cancer treatment within weeks of study treatment start (or weeks for mitomycin C, nitrosoureas and monoclonal antibodies); with exceptions. Patient who has had systemic therapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to study entry Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study; treatment with hydroxyurea is permitted during cycle to maintain white blood cell (WBC) < ,/uL Chemotherapy or dose of other potentially myelosuppressive treatment within weeks prior to Screening ( weeks for nitrosoureas or mitomycin C) Prior chemotherapy within the last weeks (last weeks for nitrosoureas/mitomycin) Patients must be >= weeks from last chemotherapy or radiation ( weeks for nitrosoureas or mitomycin) Patients who have had chemotherapy, radiation therapy, or other investigational agents within weeks prior to entering study, weeks for nitrosoureas or mitomycin Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study; hydroxyurea may be administered for count control both pre-treatment and during cycle only Patients must be at least weeks from any prior systemic therapy ( weeks for nitrosoureas or mitomycin C), surgery or radiation Patient must have recovered from toxicity of prior chemotherapy, molecularly targeted agents and/or radiotherapy; patient may not have received chemotherapy in the prior weeks ( weeks for nitrosoureas or mitomycin C); patients may have not received a molecularly targeted agent within the past weeks or half lives (which ever is less); patients may not have received radiotherapy in the prior weeks Patients must not have received nitrosoureas or mitomycin-C within days prior to sub-study registration Prior chemotherapy is allowed; patients must not have received chemotherapy for weeks prior to the initiation of study treatment and must have full recovery from any acute effects of any prior chemotherapy; patients must not have had nitrosoureas or mitomycin C for weeks prior to the initiation of study treatment Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study Systemic anticancer therapy within weeks of study entry, except for nitrosoureas or mitomycin C ( weeks). Patients must have >= weeks since prior chemotherapy or radiation (>= weeks for nitrosoureas or mitomycin C) Patient who has had systemic therapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to study entry Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study Any antitumor systemic cytotoxic therapies within days prior to enrollment ( weeks for nitrosoureas or mitomycin-C); prior high-dose chemotherapy with bone marrow or stem cell transplant is excluded Patients must be off radiation therapy or chemotherapy weeks ( weeks for nitrosoureas or mitomycin C) of starting induction chemotherapy Subjects who have had cytotoxic chemotherapy or treatment with monoclonal antibodies within weeks ( weeks for nitrosoureas or mitomycin C), radiotherapy within weeks, or other molecular targeted therapies (including tyrosine kinase inhibitors within weeks prior to entering the study) Conventional cytotoxic chemotherapy: ? weeks (? weeks for nitrosoureas and mitomycin-C) Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study; patients who have had prior onalespib or ATM as a monotherapy will not be excluded No chemotherapy within weeks prior to study treatment administration; nitrosoureas and mitomycin C are not allowed within weeks prior to initiation of study treatment Patients should not have received any chemotherapy or investigational agents for at least weeks before entering the study ( weeks for nitrosoureas or mitomycin C) < weeks for mitomycin-C or nitrosoureas Receipt of cytotoxic chemotherapy within weeks ( weeks for nitrosoureas and mitomycin C) of scheduled dosing day . Prior therapy with nitrosoureas or mitomycin within weeks prior to the first dose of TKM-. mitomycin-C or nitrosoureas within days Radiotherapy (except for palliative reasons), chemotherapy, endocrine therapy, or immunotherapy during the previous weeks ( weeks for investigational medicinal products and weeks for nitrosoureas and Mitomycin-C) before treatment. Patients who have had chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study Exposure to nitrosoureas or mitomycin C within days before the first dose of study drug. Previous anti-cancer therapy for malignancy within weeks ( weeks for the nitrosoureas or mitomycin C) before day Treatment with radiotherapy, chemotherapy or investigational therapy within month (or half lifes for cytotoxics) prior to study entry ( weeks for nitrosoureas or Mitomycin C). Received radiation therapy, surgery, or chemotherapy within weeks prior to study entry ( weeks for nitrosoureas or Mitomycin C) Chemotherapy or other systemic cancer therapy within weeks of initial study treatment ( weeks for nitrosoureas or mitomycin), or regional chemotherapy (limb infusion or perfusion) within weeks of initial study treatment Had chemotherapy or radiotherapy within weeks (or weeks for nitrosoureas or mitomycin C) prior to administration of the first dose of study treatment. Cytotoxic chemotherapy: ? the duration of the cycle of the most recent treatment regimen (a minimum of weeks for all regimens, except weeks for nitrosoureas and mitomycin-C). Immunotherapy, radiotherapy, or chemotherapy ? weeks prior to enrollment. (? weeks for nitrosoureas, mitomycin-C, and liposomal doxorubicin, and ? weeks from prior antibody therapy). Patients who have had chemotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study Have received chemotherapy or radiotherapy within weeks ( weeks for nitrosoureas or mitomycin C) prior to initiating administration of the study drugs Patients who have had chemotherapy or targeted small molecule therapy within weeks ( weeks for nitrosoureas or mitomycin C) before entering the study Prior chemotherapy is allowed; patients must not have received chemotherapy for weeks prior to the initiation of study treatment and must have full recovery from any acute effects of any prior chemotherapy; patients must not have had nitrosoureas or mitomycin C for weeks prior to the initiation of study treatment Participants who have had chemotherapy, radiotherapy, biological therapy, immunotherapy or other anticancer agents within days (six weeks for nitrosoureas or mitomycin C) prior to entering the study The patient has received chemotherapy or radiotherapy within weeks or has received nitrosoureas or mitomycin C within weeks prior to the first dose of study drug.